Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Albumin-bound Paclitaxel in Advanced cSCC
NCT05886140Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of camrelizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 60 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05886140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886140.